<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240615060937&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240615060937&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sat, 15 Jun 2024 10:09:38 +0000</lastbuilddate>
<pubDate>Fri, 14 Jun 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>BNP as a biomarker in adult congenital heart disease: help or hype?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38875016/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240615060937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 14;45(23):2076-2078. doi: 10.1093/eurheartj/ehae286.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38875016/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240615060937&v=2.18.0.post9+e462414">38875016</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae286>10.1093/eurheartj/ehae286</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38875016</guid>
<pubDate>Fri, 14 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>A Mark Richards</dc:creator>
<dc:date>2024-06-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>BNP as a biomarker in adult congenital heart disease: help or hype?</dc:title>
<dc:identifier>pmid:38875016</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae286</dc:identifier>
</item>
<item>
<title>The evolving management of adult congenital heart disease: focus on biomarkers and cardiac magnetic resonance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38875015/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240615060937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 14;45(23):2025-2028. doi: 10.1093/eurheartj/ehae366.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38875015/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240615060937&v=2.18.0.post9+e462414">38875015</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae366>10.1093/eurheartj/ehae366</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38875015</guid>
<pubDate>Fri, 14 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-06-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The evolving management of adult congenital heart disease: focus on biomarkers and cardiac magnetic resonance</dc:title>
<dc:identifier>pmid:38875015</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae366</dc:identifier>
</item>
<item>
<title>Lipid lowering for prevention of venous thromboembolism: a network meta-analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38874212/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240615060937&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The present meta-analysis of RCTs suggests that LLT may have a potential for VTE prevention, particularly in high-intensity dosing and in combination therapy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 14:ehae361. doi: 10.1093/eurheartj/ehae361. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Studies have suggested that statins may be associated with reduced risk of venous thromboembolism (VTE). The aim of the current study was to assess the evidence regarding the comparative effect of all lipid-lowering therapies (LLT) in primary VTE prevention.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: After a systematic search of PubMed, CENTRAL, and Web of Science up until 2 November 2022, randomized controlled trials (RCT) of statins (high- or low-/moderate-intensity), ezetimibe, or proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) were selected. An additive component network meta-analysis to compare VTE risk during long-term follow-up across different combinations of LLT was performed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Forty-five RCTs (n = 254 933 patients) were identified, reporting a total of 2084 VTE events. Compared with placebo, the combination of PCSK9i with high-intensity statin was associated with the largest reduction in VTE risk (risk ratio [RR] 0.59; 95% confidence interval [CI] 0.43-0.80), while there was a trend towards reduction for high-intensity (0.84; 0.70-1.02) and low-/moderate-intensity (0.89; 0.79-1.00) statin monotherapy. Ezetimibe monotherapy did not affect the VTE risk (1.04; 0.83-1.30). There was a gradual increase in the summary effect of VTE reduction with increasing intensity of the LLT. When compared with low-/moderate-intensity statin monotherapy, the combination of PCSK9i and high-intensity statin was significantly more likely to reduce VTE risk (0.66; 0.49-0.89).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The present meta-analysis of RCTs suggests that LLT may have a potential for VTE prevention, particularly in high-intensity dosing and in combination therapy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38874212/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240615060937&v=2.18.0.post9+e462414">38874212</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae361>10.1093/eurheartj/ehae361</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38874212</guid>
<pubDate>Fri, 14 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Ioannis T Farmakis</dc:creator>
<dc:creator>Konstantinos C Christodoulou</dc:creator>
<dc:creator>Lukas Hobohm</dc:creator>
<dc:creator>Stavros V Konstantinides</dc:creator>
<dc:creator>Luca Valerio</dc:creator>
<dc:date>2024-06-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Lipid lowering for prevention of venous thromboembolism: a network meta-analysis</dc:title>
<dc:identifier>pmid:38874212</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae361</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: do we need beta-blockers after myocardial infarction with preserved ejection fraction?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38874207/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240615060937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 14:ehae368. doi: 10.1093/eurheartj/ehae368. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38874207/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240615060937&v=2.18.0.post9+e462414">38874207</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae368>10.1093/eurheartj/ehae368</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38874207</guid>
<pubDate>Fri, 14 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Massimo Volpe</dc:creator>
<dc:date>2024-06-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: do we need beta-blockers after myocardial infarction with preserved ejection fraction?</dc:title>
<dc:identifier>pmid:38874207</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae368</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: Plastic particles in carotid plaques-inactive debris or predictors of cardiovascular events?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38874197/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240615060937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 14:ehae307. doi: 10.1093/eurheartj/ehae307. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38874197/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240615060937&v=2.18.0.post9+e462414">38874197</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae307>10.1093/eurheartj/ehae307</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38874197</guid>
<pubDate>Fri, 14 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Giovanna Liuzzo</dc:creator>
<dc:creator>Carlo Patrono</dc:creator>
<dc:date>2024-06-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: Plastic particles in carotid plaques-inactive debris or predictors of cardiovascular events?</dc:title>
<dc:identifier>pmid:38874197</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae307</dc:identifier>
</item>
<item>
<title>Eight reasons why lipoprotein(a) should be measured in everyone at least once in a lifetime</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38874175/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240615060937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 14:ehae191. doi: 10.1093/eurheartj/ehae191. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38874175/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240615060937&v=2.18.0.post9+e462414">38874175</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae191>10.1093/eurheartj/ehae191</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38874175</guid>
<pubDate>Fri, 14 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Benoit J Arsenault</dc:creator>
<dc:creator>Pia R Kamstrup</dc:creator>
<dc:date>2024-06-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Eight reasons why lipoprotein(a) should be measured in everyone at least once in a lifetime</dc:title>
<dc:identifier>pmid:38874175</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae191</dc:identifier>
</item>
<item>
<title>Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38873793/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240615060937&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Icosapent ethyl treatment resulted in a numerically lower risk of cardiovascular events that did not reach statistical significance in patients with chronic coronary artery disease, a low EPA/AA ratio, and statin treatment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 14. doi: 10.1161/CIRCULATIONAHA.123.065520. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Low plasma levels of eicosapentaenoic acid (EPA) are associated with cardiovascular events. This trial aimed to assess the clinical benefits of icosapent ethyl in patients with coronary artery disease, a low EPA/arachidonic acid (AA) ratio, and statin treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this prospective, multicenter, randomized, open-label, blinded end-point study, patients with stable coronary artery disease and a low EPA/AA ratio (&lt;0.4) were randomized to EPA (1800 of icosapent ethyl administered daily) or control group. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, unstable angina pectoris, and coronary revascularization. The secondary composite end points of coronary events included sudden cardiac death, fatal and nonfatal myocardial infarction, unstable angina requiring emergency hospitalization and coronary revascularization, or coronary revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 3884 patients were enrolled at 95 sites in Japan. Among them, 2506 patients had a low EPA/AA ratio, and 1249 and 1257 patients were randomized to the EPA and control group, respectively. The median EPA/AA ratio was 0.243 (interquartile range, 0.180-0.314) and 0.235 (interquartile range, 0.163-0.310) in the EPA and control group, respectively. Over a median period of 5 years, the primary end point occurred in 112 of 1225 patients (9.1%) and 155 of 1235 patients (12.6%) in the EPA and control group, respectively (hazard ratio, 0.79 [95% CI, 0.62-1.00]; <i>P</i>=0.055). Meanwhile, the secondary composite end point of coronary events in the EPA group was significantly lower (81/1225 [6.6%] versus 120/1235 [9.7%] patients; hazard ratio, 0.73 [95% CI, 0.55-0.97]). Adverse events did not differ between the groups, but the rate of new-onset atrial fibrillation was significantly higher in the EPA group (3.1% versus 1.6%; <i>P</i>=0.017).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Icosapent ethyl treatment resulted in a numerically lower risk of cardiovascular events that did not reach statistical significance in patients with chronic coronary artery disease, a low EPA/AA ratio, and statin treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.umin.ac.jp/ctr/; Unique identifier: UMIN000012069.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38873793/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240615060937&v=2.18.0.post9+e462414">38873793</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065520>10.1161/CIRCULATIONAHA.123.065520</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38873793</guid>
<pubDate>Fri, 14 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Katsumi Miyauchi</dc:creator>
<dc:creator>Hiroshi Iwata</dc:creator>
<dc:creator>Yuji Nishizaki</dc:creator>
<dc:creator>Teruo Inoue</dc:creator>
<dc:creator>Atsushi Hirayama</dc:creator>
<dc:creator>Kazuo Kimura</dc:creator>
<dc:creator>Yukio Ozaki</dc:creator>
<dc:creator>Toyoaki Murohara</dc:creator>
<dc:creator>Kenji Ueshima</dc:creator>
<dc:creator>Yoshihiro Kuwabara</dc:creator>
<dc:creator>Sachiko Tanaka-Mizuno</dc:creator>
<dc:creator>Naotake Yanagisawa</dc:creator>
<dc:creator>Tosiya Sato</dc:creator>
<dc:creator>Hiroyuki Daida</dc:creator>
<dc:creator>RESPECT-EPA Investigators</dc:creator>
<dc:date>2024-06-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA)</dc:title>
<dc:identifier>pmid:38873793</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065520</dc:identifier>
</item>
<item>
<title>Endothelial Heterogeneity in the Response to Autophagy Drives Small Vessel Muscularization in Pulmonary Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38873770/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240615060937&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Autophagic activation by hypoxia induces in parallel PAEC proliferation and MVEC apoptosis. These differential responses cause a progressive replacement of MVECs by PAECs in precapillary pulmonary arterioles, thus providing a macrovascular context that in turn promotes pulmonary artery smooth muscle cell proliferation and migration, ultimately driving distal vessel muscularization and the development of PH.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 14. doi: 10.1161/CIRCULATIONAHA.124.068726. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Endothelial cell (EC) apoptosis and proliferation of apoptosis-resistant cells is a hallmark of pulmonary hypertension (PH). Yet, why some ECs die and others proliferate and how this contributes to vascular remodeling is unclear. We hypothesized that this differential response may: (1) relate to different EC subsets, namely pulmonary artery (PAECs) versus microvascular ECs (MVECs); (2) be attributable to autophagic activation in both EC subtypes; and (3) cause replacement of MVECs by PAECs with subsequent distal vessel muscularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: EC subset responses to chronic hypoxia were assessed by single-cell RNA sequencing of murine lungs. Proliferative versus apoptotic responses, activation, and role of autophagy were assessed in human and rat PAECs and MVECs, and in precision-cut lung slices of wild-type mice or mice with endothelial deficiency in the autophagy gene <i>Atg7</i> (<i>Atg7</i><sup>EN-KO</sup>). Abundance of PAECs versus MVECs in precapillary microvessels was assessed in lung tissue from patients with PH and animal models on the basis of structural or surface markers.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In vitro and in vivo, PAECs proliferated in response to hypoxia, whereas MVECs underwent apoptosis. Single-cell RNA sequencing analyses support these findings in that hypoxia induced an antiapoptotic, proliferative phenotype in arterial ECs, whereas capillary ECs showed a propensity for cell death. These distinct responses were prevented in hypoxic <i>Atg7</i><sup>EN-KO</sup> mice or after <i>ATG7</i> silencing, yet replicated by autophagy stimulation. In lung tissue from mice, rats, or patients with PH, the abundance of PAECs in precapillary arterioles was increased, and that of MVECs reduced relative to controls, indicating replacement of microvascular by macrovascular ECs. EC replacement was prevented by genetic or pharmacological inhibition of autophagy in vivo. Conditioned medium from hypoxic PAECs yet not MVECs promoted pulmonary artery smooth muscle cell proliferation and migration in a platelet-derived growth factor-dependent manner. Autophagy inhibition attenuated PH development and distal vessel muscularization in preclinical models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Autophagic activation by hypoxia induces in parallel PAEC proliferation and MVEC apoptosis. These differential responses cause a progressive replacement of MVECs by PAECs in precapillary pulmonary arterioles, thus providing a macrovascular context that in turn promotes pulmonary artery smooth muscle cell proliferation and migration, ultimately driving distal vessel muscularization and the development of PH.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38873770/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240615060937&v=2.18.0.post9+e462414">38873770</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068726>10.1161/CIRCULATIONAHA.124.068726</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38873770</guid>
<pubDate>Fri, 14 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Qi Zhang</dc:creator>
<dc:creator>Nobuhiro Yaoita</dc:creator>
<dc:creator>Arata Tabuchi</dc:creator>
<dc:creator>Shaofei Liu</dc:creator>
<dc:creator>Shiau-Haln Chen</dc:creator>
<dc:creator>Qiuhua Li</dc:creator>
<dc:creator>Niklas Hegemann</dc:creator>
<dc:creator>Caihong Li</dc:creator>
<dc:creator>Julie Rodor</dc:creator>
<dc:creator>Sara Timm</dc:creator>
<dc:creator>Hebatullah Laban</dc:creator>
<dc:creator>Toren Finkel</dc:creator>
<dc:creator>Troy Stevens</dc:creator>
<dc:creator>Diego F Alvarez</dc:creator>
<dc:creator>Lasti Erfinanda</dc:creator>
<dc:creator>Marc de Perrot</dc:creator>
<dc:creator>Mariya M Kucherenko</dc:creator>
<dc:creator>Christoph Knosalla</dc:creator>
<dc:creator>Matthias Ochs</dc:creator>
<dc:creator>Stefanie Dimmeler</dc:creator>
<dc:creator>Thomas Korff</dc:creator>
<dc:creator>Subodh Verma</dc:creator>
<dc:creator>Andrew H Baker</dc:creator>
<dc:creator>Wolfgang M Kuebler</dc:creator>
<dc:date>2024-06-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Endothelial Heterogeneity in the Response to Autophagy Drives Small Vessel Muscularization in Pulmonary Hypertension</dc:title>
<dc:identifier>pmid:38873770</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068726</dc:identifier>
</item>
<item>
<title>The Ubiquitin Ligase RBX2/SAG Regulates Mitochondrial Ubiquitination and Mitophagy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38873758/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240615060937&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings identify RBX2-CRL5 as a mitochondrial Ub ligase that regulates mitophagy and cardiac homeostasis in a Parkin-independent, PINK1-dependent manner.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 14. doi: 10.1161/CIRCRESAHA.124.324285. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Clearance of damaged mitochondria via mitophagy is crucial for cellular homeostasis. Apart from Parkin, little is known about additional Ub (ubiquitin) ligases that mediate mitochondrial ubiquitination and turnover, particularly in highly metabolically active organs such as the heart.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this study, we have combined in silico analysis and biochemical assay to identify CRL (cullin-RING ligase) 5 as a mitochondrial Ub ligase. We generated cardiomyocytes and mice lacking RBX2 (RING-box protein 2; also known as SAG [sensitive to apoptosis gene]), a catalytic subunit of CRL5, to understand the effects of RBX2 depletion on mitochondrial ubiquitination, mitophagy, and cardiac function. We also performed proteomics analysis and RNA-sequencing analysis to define the impact of loss of RBX2 on the proteome and transcriptome.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: RBX2 and CUL (cullin) 5, 2 core components of CRL5, localize to mitochondria. Depletion of RBX2 inhibited mitochondrial ubiquitination and turnover, impaired mitochondrial membrane potential and respiration, increased cardiomyocyte cell death, and has a global impact on the mitochondrial proteome. In vivo, deletion of the <i>Rbx2</i> gene in adult mouse hearts suppressed mitophagic activity, provoked accumulation of damaged mitochondria in the myocardium, and disrupted myocardial metabolism, leading to the rapid development of dilated cardiomyopathy and heart failure. Similarly, ablation of RBX2 in the developing heart resulted in dilated cardiomyopathy and heart failure. The action of RBX2 in mitochondria is not dependent on Parkin, and Parkin gene deletion had no impact on the onset and progression of cardiomyopathy in RBX2-deficient hearts. Furthermore, RBX2 controls the stability of PINK1 in mitochondria.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings identify RBX2-CRL5 as a mitochondrial Ub ligase that regulates mitophagy and cardiac homeostasis in a Parkin-independent, PINK1-dependent manner.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38873758/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240615060937&v=2.18.0.post9+e462414">38873758</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324285>10.1161/CIRCRESAHA.124.324285</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38873758</guid>
<pubDate>Fri, 14 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Wenjuan Wang</dc:creator>
<dc:creator>Ermin Li</dc:creator>
<dc:creator>Jianqiu Zou</dc:creator>
<dc:creator>Chen Qu</dc:creator>
<dc:creator>Juan Ayala</dc:creator>
<dc:creator>Yuan Wen</dc:creator>
<dc:creator>Md Sadikul Islam</dc:creator>
<dc:creator>Neal L Weintraub</dc:creator>
<dc:creator>David J Fulton</dc:creator>
<dc:creator>Qiangrong Liang</dc:creator>
<dc:creator>Jiliang Zhou</dc:creator>
<dc:creator>Jinbao Liu</dc:creator>
<dc:creator>Jie Li</dc:creator>
<dc:creator>Yi Sun</dc:creator>
<dc:creator>Huabo Su</dc:creator>
<dc:date>2024-06-14</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>The Ubiquitin Ligase RBX2/SAG Regulates Mitochondrial Ubiquitination and Mitophagy</dc:title>
<dc:identifier>pmid:38873758</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324285</dc:identifier>
</item>
<item>
<title>Correction of age-associated defects in dendritic cells enables CD4&lt;sup>;+&lt;/sup>; T cells to eradicate tumors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38870946/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240615060937&amp;v=2.18.0.post9+e462414
      <description>Defective host defenses later in life are associated with changes in immune cell activities, suggesting that age-specific considerations are needed in immunotherapy approaches. In this study, we found that PD-1 and CTLA4-based cancer immunotherapies are unable to eradicate tumors in elderly mice. This defect in anti-tumor activity correlated with two known age-associated immune defects: diminished abundance of systemic naive CD8^(+) T cells and weak migratory activities of dendritic cells (DCs)....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 9:S0092-8674(24)00535-X. doi: 10.1016/j.cell.2024.05.026. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Defective host defenses later in life are associated with changes in immune cell activities, suggesting that age-specific considerations are needed in immunotherapy approaches. In this study, we found that PD-1 and CTLA4-based cancer immunotherapies are unable to eradicate tumors in elderly mice. This defect in anti-tumor activity correlated with two known age-associated immune defects: diminished abundance of systemic naive CD8<sup>+</sup> T cells and weak migratory activities of dendritic cells (DCs). We identified a vaccine adjuvant, referred to as a DC hyperactivator, which corrects DC migratory defects in the elderly. Vaccines containing tumor antigens and DC hyperactivators induced T helper type 1 (TH1) CD4<sup>+</sup> T cells with cytolytic activity that drive anti-tumor immunity in elderly mice. When administered early in life, DC hyperactivators were the only adjuvant identified that elicited anti-tumor CD4<sup>+</sup> T cells that persisted into old age. These results raise the possibility of correcting age-associated immune defects through DC manipulation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38870946/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240615060937&v=2.18.0.post9+e462414">38870946</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.026>10.1016/j.cell.2024.05.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38870946</guid>
<pubDate>Thu, 13 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Dania Zhivaki</dc:creator>
<dc:creator>Stephanie N Kennedy</dc:creator>
<dc:creator>Josh Park</dc:creator>
<dc:creator>Francesco Boriello</dc:creator>
<dc:creator>Pascal Devant</dc:creator>
<dc:creator>Anh Cao</dc:creator>
<dc:creator>Kristin M Bahleda</dc:creator>
<dc:creator>Shane Murphy</dc:creator>
<dc:creator>Cristin McCabe</dc:creator>
<dc:creator>Charles L Evavold</dc:creator>
<dc:creator>Kate L Chapman</dc:creator>
<dc:creator>Ivan Zanoni</dc:creator>
<dc:creator>Orr Ashenberg</dc:creator>
<dc:creator>Ramnik J Xavier</dc:creator>
<dc:creator>Jonathan C Kagan</dc:creator>
<dc:date>2024-06-13</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Correction of age-associated defects in dendritic cells enables CD4&lt;sup>;+&lt;/sup>; T cells to eradicate tumors</dc:title>
<dc:identifier>pmid:38870946</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.026</dc:identifier>
</item>
<item>
<title>A pseudoautosomal glycosylation disorder prompts the revision of dolichol biosynthesis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38870945/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240615060937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 12:S0092-8674(24)00644-5. doi: 10.1016/j.cell.2024.06.004. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38870945/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240615060937&v=2.18.0.post9+e462414">38870945</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.004>10.1016/j.cell.2024.06.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38870945</guid>
<pubDate>Thu, 13 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Matthew P Wilson</dc:creator>
<dc:creator>Takfarinas Kentache</dc:creator>
<dc:creator>Charlotte R Althoff</dc:creator>
<dc:creator>Céline Schulz</dc:creator>
<dc:creator>Geoffroy de Bettignies</dc:creator>
<dc:creator>Gisèle Mateu Cabrera</dc:creator>
<dc:creator>Loreta Cimbalistiene</dc:creator>
<dc:creator>Birute Burnyte</dc:creator>
<dc:creator>Grace Yoon</dc:creator>
<dc:creator>Gregory Costain</dc:creator>
<dc:creator>Sandrine Vuillaumier-Barrot</dc:creator>
<dc:creator>David Cheillan</dc:creator>
<dc:creator>Daisy Rymen</dc:creator>
<dc:creator>Lucie Rychtarova</dc:creator>
<dc:creator>Hana Hansikova</dc:creator>
<dc:creator>Marina Bury</dc:creator>
<dc:creator>Joseph P Dewulf</dc:creator>
<dc:creator>Francesco Caligiore</dc:creator>
<dc:creator>Jaak Jaeken</dc:creator>
<dc:creator>Vincent Cantagrel</dc:creator>
<dc:creator>Emile Van Schaftingen</dc:creator>
<dc:creator>Gert Matthijs</dc:creator>
<dc:creator>François Foulquier</dc:creator>
<dc:creator>Guido T Bommer</dc:creator>
<dc:date>2024-06-13</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A pseudoautosomal glycosylation disorder prompts the revision of dolichol biosynthesis</dc:title>
<dc:identifier>pmid:38870945</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.004</dc:identifier>
</item>
<item>
<title>Retraction Notice to: Genomic Decoding of Neuronal Depolarization by Stimulus-Specific NPAS4 Heterodimers</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38870944/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240615060937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 12:S0092-8674(24)00648-2. doi: 10.1016/j.cell.2024.06.008. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38870944/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240615060937&v=2.18.0.post9+e462414">38870944</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.008>10.1016/j.cell.2024.06.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38870944</guid>
<pubDate>Thu, 13 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>G Stefano Brigidi</dc:creator>
<dc:creator>Michael G B Hayes</dc:creator>
<dc:creator>Nathaniel P Delos Santos</dc:creator>
<dc:creator>Andrea L Hartzell</dc:creator>
<dc:creator>Lorane Texari</dc:creator>
<dc:creator>Pei-Ann Lin</dc:creator>
<dc:creator>Anna Bartlett</dc:creator>
<dc:creator>Joseph R Ecker</dc:creator>
<dc:creator>Christopher Benner</dc:creator>
<dc:creator>Sven Heinz</dc:creator>
<dc:creator>Brenda L Bloodgood</dc:creator>
<dc:date>2024-06-13</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Retraction Notice to: Genomic Decoding of Neuronal Depolarization by Stimulus-Specific NPAS4 Heterodimers</dc:title>
<dc:identifier>pmid:38870944</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.008</dc:identifier>
</item>
<item>
<title>Epigenetic changes in HSCs contribute to HF and comorbidities</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38866904/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240615060937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jun 12. doi: 10.1038/s41569-024-01051-9. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38866904/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240615060937&v=2.18.0.post9+e462414">38866904</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01051-9>10.1038/s41569-024-01051-9</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38866904</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Epigenetic changes in HSCs contribute to HF and comorbidities</dc:title>
<dc:identifier>pmid:38866904</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01051-9</dc:identifier>
</item>
<item>
<title>RNA and the emerging potential of bio-inspired molecules in cardiovascular disease therapies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38866524/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240615060937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 13:ehae348. doi: 10.1093/eurheartj/ehae348. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38866524/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240615060937&v=2.18.0.post9+e462414">38866524</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae348>10.1093/eurheartj/ehae348</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38866524</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Noreen Ahmed</dc:creator>
<dc:creator>Darryl R Davis</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>RNA and the emerging potential of bio-inspired molecules in cardiovascular disease therapies</dc:title>
<dc:identifier>pmid:38866524</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae348</dc:identifier>
</item>
<item>
<title>Sex-related differences in degenerative mitral regurgitation: a call to action</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38866496/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240615060937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 13:ehae360. doi: 10.1093/eurheartj/ehae360. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38866496/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240615060937&v=2.18.0.post9+e462414">38866496</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae360>10.1093/eurheartj/ehae360</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38866496</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Sex-related differences in degenerative mitral regurgitation: a call to action</dc:title>
<dc:identifier>pmid:38866496</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae360</dc:identifier>
</item>
<item>
<title>Reply: Use of Percutaneous Therapies as a Bridge to Surgery in Patients With Right-Sided Infective Endocarditis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38866453/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240615060937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 18;83(24):e241. doi: 10.1016/j.jacc.2024.04.019.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38866453/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240615060937&v=2.18.0.post9+e462414">38866453</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.019>10.1016/j.jacc.2024.04.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38866453</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Haytham Elgharably</dc:creator>
<dc:creator>Steven Gordon</dc:creator>
<dc:creator>Joanna Ghobrial</dc:creator>
<dc:creator>Gösta B Pettersson</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Use of Percutaneous Therapies as a Bridge to Surgery in Patients With Right-Sided Infective Endocarditis</dc:title>
<dc:identifier>pmid:38866453</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.019</dc:identifier>
</item>
<item>
<title>Use of Percutaneous Therapies as a Bridge to Surgery in Patients With Right-Sided Infective Endocarditis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38866452/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240615060937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 18;83(24):e239. doi: 10.1016/j.jacc.2024.03.428.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38866452/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240615060937&v=2.18.0.post9+e462414">38866452</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.428>10.1016/j.jacc.2024.03.428</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38866452</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>V Seenu Reddy</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Use of Percutaneous Therapies as a Bridge to Surgery in Patients With Right-Sided Infective Endocarditis</dc:title>
<dc:identifier>pmid:38866452</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.428</dc:identifier>
</item>
<item>
<title>Turning Data Into Action: The JACC Global Burden of Cardiovascular Diseases and Risks Interactive Tool and Resources</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38866451/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240615060937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 18;83(24):2610-2613. doi: 10.1016/j.jacc.2024.05.007.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38866451/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240615060937&v=2.18.0.post9+e462414">38866451</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.007>10.1016/j.jacc.2024.05.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38866451</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>George A Mensah</dc:creator>
<dc:creator>Taryn Myers</dc:creator>
<dc:creator>Ron Schmelzer</dc:creator>
<dc:creator>Shlomo Spaeth</dc:creator>
<dc:creator>Gregory A Roth</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Turning Data Into Action: The JACC Global Burden of Cardiovascular Diseases and Risks Interactive Tool and Resources</dc:title>
<dc:identifier>pmid:38866451</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.007</dc:identifier>
</item>
<item>
<title>Gender Diversity in Cardiovascular Journal Authorship: So Much Time, So Little Progress</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38866450/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240615060937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 18;83(24):2469-2471. doi: 10.1016/j.jacc.2024.04.020.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38866450/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240615060937&v=2.18.0.post9+e462414">38866450</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.020>10.1016/j.jacc.2024.04.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38866450</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Mary Norine Walsh</dc:creator>
<dc:creator>JoAnn Lindenfeld</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Gender Diversity in Cardiovascular Journal Authorship: So Much Time, So Little Progress</dc:title>
<dc:identifier>pmid:38866450</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.020</dc:identifier>
</item>
<item>
<title>Geographic Mapping of Gender Disparities in Authorship of Cardiovascular Literature</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38866449/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240615060937&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Over the past decade, the proportion of women authors across all article types in major cardiovascular journals remained low. A call to action is needed to promote women in cardiology and provide them with equitable opportunities.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 18;83(24):2458-2468. doi: 10.1016/j.jacc.2024.03.427.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Women in cardiology experience considerable gender disparities in publications, which hinders their career advancements to higher faculty and senior leadership positions. However, the extent of these disparities across different types of cardiovascular literature is not well understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We investigated gender differences in authorship across various cardiovascular publications over a decade and examined geographic variations in the representation of women authors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: All papers published from January 1, 2010, to December 31, 2019, in 4 major cardiovascular journals (Journal of the American College of Cardiology, European Heart Journal, Journal of the American Medical Association Cardiology, and Nature Reviews Cardiology) were reviewed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of the 18,535 papers with 111,562 authors, 20.6% of the authors were women, and 47.7% of the papers had no women authors. Over 10 years, the proportion of women authors remained low (20.7% in 2010 to 21.4% in 2019), with the lowest proportion in editorial papers (14.8%) and the highest in research papers (21.8%). More women as first (34.6%) and last (47.6%) authors were affiliated with institutions in the United States compared with other countries. The proportion of women middle-order authors was higher on papers with women as first authors (29.4% vs 20.5%) or last authors (30.6% vs 21.3%), compared with papers with men as first or last authors, respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Over the past decade, the proportion of women authors across all article types in major cardiovascular journals remained low. A call to action is needed to promote women in cardiology and provide them with equitable opportunities.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38866449/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240615060937&v=2.18.0.post9+e462414">38866449</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.427>10.1016/j.jacc.2024.03.427</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38866449</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Ridhima Goel</dc:creator>
<dc:creator>Samantha Sartori</dc:creator>
<dc:creator>Birgit Vogel</dc:creator>
<dc:creator>Kimberly Okoli</dc:creator>
<dc:creator>Kayla Franklin-Bedel</dc:creator>
<dc:creator>Rebecca Ortega</dc:creator>
<dc:creator>Dee Dee Wang</dc:creator>
<dc:creator>Pamela S Douglas</dc:creator>
<dc:creator>Tracy Y Wang</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Women As One Scientific Expert Panel</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Geographic Mapping of Gender Disparities in Authorship of Cardiovascular Literature</dc:title>
<dc:identifier>pmid:38866449</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.427</dc:identifier>
</item>
<item>
<title>Equitable Health Care for Children: The Next Horizon of Change</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38866448/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240615060937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 18;83(24):2455-2457. doi: 10.1016/j.jacc.2024.04.032.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38866448/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240615060937&v=2.18.0.post9+e462414">38866448</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.032>10.1016/j.jacc.2024.04.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38866448</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Meena Nathan</dc:creator>
<dc:creator>Emily Bucholz</dc:creator>
<dc:creator>Katie M Moynihan</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Equitable Health Care for Children: The Next Horizon of Change</dc:title>
<dc:identifier>pmid:38866448</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.032</dc:identifier>
</item>





























</channel>
</rss>